MedTrace Logo

CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

NCT06964568 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 452

Last updated 2026-04-17

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if concurrent chemoradiotherapy followed by immunotherapy as maintenance therapy works to treat locally advanced esophageal squamous cell cancer in adults.

Conditions

  • Esophageal Carcinoma
  • Radiotherapy
  • Immunotherapy

Interventions

DRUG

PD-1 inhibitor

PD-1 inhibitors will be administered intravenously, a fixed dose of 200 mg, once every 3 weeks for 1 year.

RADIATION

Unlimited radiotherapy

Unlimited radiotherapy 50.4Gy/28Fx

DRUG

TP regimen

Chemotherapy: Paclitaxel 135mg/m2 d1+cisplatin 25mg/m2 d1-3 q28d

RADIATION

TDLN-sparing radiotherapy

Tumor draining lymph nodes-sparing radiotherapy 50.4Gy/28Fx

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2029-02-28
Completion
2031-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06964568 on ClinicalTrials.gov